Physician Attitudes on Kidney Biopsies for Research: A Survey Study.
Physician Attitudes on Kidney Biopsies for Research: A Survey Study.
复制标题
医生对用于研究的肾脏活检的态度：一项调查研究。
DOI：
10.1016/j.xkme.2019.10.009
复制
发表时间：
2020
期刊：
影响因子：
3.9
通讯作者：
Waikar,SushrutS
中科院分区：
文献类型：
--
作者：
McMahon,GearoidM;Amodu,Afolarin;Sise,MeghanE;Mothi,SurajSarvode;Palsson,Ragnar;Waikar,SushrutS
肾活检是诊断许多肾脏疾病的金标准，但只有一小部分患者接受这种侵入性手术。1严重出血是活检的主要并发症。2，3最近对用于研究目的的肾活检的兴趣提出了参与者的安全问题。4为了了解医生如何看待肾脏活检的风险，我们向波士顿1家学术医院的60名住院医师和波士顿3家学术医院的98名肾脏科医生发送了一项机构审查委员会批准的匿名在线调查。调查参与者被问及他们的临床经验，他们认为肾活检的风险，以及他们支持从他们的病人身上获得活检用于研究目的的可能性。总的回答率为46%（15/60住院医生和57/98肾科医生）。29名（51%）肾科医生具有临床、研究和管理角色。12人（21%）被确定为临床医生，16人（28%）被确定为研究人员。28人（47%）从业时间超过10年。除1名住院医生外，所有住院医生的患者在过去5年内均接受过肾活检。3名（5%）肾科医生从未进行过活检，12名（21%）进行了10次或更少的活检，25名（44%）进行了11至50次活检，17名（30%）进行了50次以上的活检。
Kidney biopsy is the gold standard for diagnosing many kidney diseases, but only a minute fraction of patients undergoes this invasive procedure. 1 Severe bleeding is a major complication associated with biopsy. 2, 3 Recent interest in kidney biopsies for research purposes has raised the question of safety for participants. 4 To understand how physicians perceive the risks of kidney biopsy, we sent an institutional review board–approved anonymous online survey to 60 hospitalists at 1 academic hospital in Boston and 98 nephrologists at 3 academic hospitals in Boston. Survey participants were asked about their clinical experience, their perceived risk of kidney biopsies, and the likelihood that they would support biopsies being obtained from their patients for research purposes.The overall response rate was 46%(15/60 hospitalists and 57/98 nephrologists). Twenty-nine (51%) nephrologists had mixed clinical, research, and administrative roles. Twelve (21%) identified as clinicians, and 16 (28%), as researchers. Twenty-eight (47%) were in practice for more than 10 years. All but 1 of the hospitalists had a patient who had undergone a kidney biopsy in the previous 5 years. Three (5%) nephrologists had never done a biopsy, 12 (21%) had performed 10 or fewer, 25 (44%) had performed 11 to 50, and 17 (30%) had performed more than 50 biopsies.